Early sputum bacterial load dynamics predict treatment response in multidrug-resistant/rifampicin-resistant tuberculosis: a multicenter prospective cohort study.

Authors

Fuzhen Zhang, Zilong Yang, Min Jiang, Xiaomeng Hu, Jun Li, Kewei Liu, Yilin Wang, Yan Hu, Yu Dong, Mingyang Qin, Qiang Li, Liang Li, Yu Pang

Published in

The Journal of infection. Pages 106838. Aug 22, 2026. Epub Aug 22, 2026.

Abstract

Early assessment of treatment response is critical for optimizing the management of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). We aimed to establish a molecular bacterial load assay (MBLA) and evaluate early bacterial load dynamics for predicting 6-month treatment response.
A multicenter prospective cohort study enrolled patients with MDR/RR-TB in China. MBLA was established and validated against conventional culture methods. Generalized linear mixed models (GLMM) and artificial neural network (ANN) models were constructed by integrating 14-day and 2-month bacterial load changes, and evaluated using area under the curve (AUC), accuracy, sensitivity, specificity, and F1 score.
MBLA enabled quantification within 24hours and strongly correlated with conventional culture (r = 0.792, -0.790; both P < 0.001). Patients with 6-month sputum culture conversion showed a rapid decline in sputum bacterial load, especially within the first 14 days after treatment initiation. Sputum bacterial load changes over the first 14 days of treatment yielded acceptable prognostic performance for predicting 6-month treatment response, albeit inferior to those obtained at 2 months. The ANN model outperformed the GLMM, with testing set AUCs of 0.91 (14-day) and 0.98 (2-month).
MBLA enables rapid quantification of viable sputum bacterial load. The ANN model incorporating 14-day bacterial load dynamics achieves a favorable AUC for predicting 6-month sputum culture conversion. It may only serve as an auxiliary early-warning indicator to supplement routine clinical assessment for MDR/RR-TB patients. Prospective interventional trials and independent external validation are required before any consideration of its use to inform personalised anti-tuberculosis treatment decisions.

PMID:
42632488
Bibliographic data and abstract were imported from PubMed on 23 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.